Stacey Stein

5.8k citations

74 papers · 1.4k indexed · h-index 18

Impact in

Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers

Papers in ⓘ

Hepatology 22
- Hepatocellular Carcinoma Treatment and Prognosis 19
Oncology 53
- Colorectal Cancer Treatments and Studies 20
- Pancreatic and Hepatic Oncology Research 18
- Cancer Treatment and Pharmacology 12
- Cancer Immunotherapy and Biomarkers 9

Co-authors: Jill Lacy (30 shared papers)Howard S. Höchster (22 shared papers)Hyun S. Kim (11 shared papers)Xiangyu Cong (8 shared papers)Johannes Uhlig (9 shared papers)Marcia S. Brose (1 shared paper)Catherine Frenette (1 shared paper)Stephen J. O’Keefe (1 shared paper)
Journals: Journal of Clinical Oncology (22 papers)Annals of Oncology (7 papers)European Radiology (3 papers)Cancer Medicine (3 papers)Cancer (2 papers)
Partner nations: United States Germany South Korea

In The Last Decade

Stacey Stein

74 papers receiving 1.4k citations

Peers

Countries citing papers authored by Stacey Stein

Since Specialization

Citations

This map shows the geographic impact of Stacey Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey Stein more than expected).

Fields of papers citing papers by Stacey Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey Stein. The network helps show where Stacey Stein may publish in the future.

Co-authors

The 25 scholars most cited alongside Stacey Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stacey Stein Line = papers co-authored together Stacey Stein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 74 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer British Journal of Cancer ·Stacey Stein, Edward James, Yanhong Deng, Xiangyu Cong, Jeremy Kortmansky, Li Jia, Carol Staugaard, Doddamane Indukala, Ann Marie Boustani, Vatsal Patel, Charles Cha, Ronald R. Salem, Bryan Chang, Howard S. Höchster, Jill Lacy	2016	153
2	FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity Medical Oncology ·Krishna S. Gunturu, Xiaopan Yao, Xiangyu Cong, Jaykumar Thumar, Howard S. Höchster, Stacey Stein, Jill Lacy	2012	115
3	Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective Seminars in Oncology ·Marcia S. Brose, Catherine Frenette, Stephen J. O’Keefe, Stacey Stein	2014	102
4	Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Journal of Clinical Oncology ·Stacey Stein, Michael J. Pishvaian, Michael Sangmin Lee, Kyung-Hun Lee, Sairy Hernandez, Antonia Kwan, Bo Liu, William Grossman, Koho Iizuka, Baek‐Yeol Ryoo	2018	91
5	Haploinsufficiency ofMSX1: a Mechanism for Selective Tooth Agenesis Molecular and Cellular Biology ·Gezhi Hu, Heleni Vastardis, Andrew J. Bendall, Zhaoqing Wang, Malcolm Logan, Hailan Zhang, Craig Nelson, Stacey Stein, Norma J. Greenfield, Christine E. Seidman, Jonathan G. Seidman, Cory Abate‐Shen	1998	74
6	Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer Breast Cancer Research ·Jasmeet Singh, Yelena Novik, Stacey Stein, Matthew Volm, Marlene Meyers, Julia Smith, Coral Omene, James L. Speyer, Robert J. Schneider, Komal Jhaveri, Silvia C. Formenti, Victoria Kyriakou, Benson Joseph, Judith D. Goldberg, Xiaochun Li, Sylvia Adams, Amy Tiersten	2014	68
7	Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC) Annals of Oncology ·Michael J. Pishvaian, M.S. Lee, Baek‐Yeol Ryoo, Stacey Stein, Ki Hoon Lee, Wendy Verret, Jessica Spahn, Hui Shao, B. Liu, Kunio Iizuka, Chih‐Hung Hsu	2018	62
8	Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC) Annals of Oncology ·M. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, B. Liu, Hesham Abdullah, Ruth He, Ki Hoon Lee	2019	62
9	Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity Experimental Hematology and Oncology ·Yue Zhang, Howard S. Höchster, Stacey Stein, Jill Lacy	2015	48
10	Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database European Radiology ·Johannes Uhlig, Cortlandt M. Sellers, Stacey Stein, Hyun S. Kim	2018	47
11	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer Clinical Cancer Research ·Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca A. Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda	2020	46
12	Patient preferences regarding incidental genomic findings discovered during tumor profiling Cancer ·Melinda Yushak, Gang Han, Sara Bouberhan, Lianne Epstein, Michael P. DiGiovanna, Sarah S. Mougalian, Tara Sanft, Maysa Abu‐Khalaf, Gina G. Chung, Stacey Stein, Sarah B. Goldberg, Lajos Pusztai, Erin Hofstatter	2016	35
13	Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers Molecular Cancer Therapeutics ·Samuel J. Klempner, Johanna C. Bendell, Victoria Villaflor, Laura Tenner, Stacey Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya Chaney, John H. Strickler	2021	34
14	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions Liver Cancer ·Meaghan Dendy, Johannes Ludwig, Stacey Stein, Hyun S. Kim	2019	33
15	Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease Cancer Medicine ·Cortlandt M. Sellers, Johannes Uhlig, Johannes Ludwig, Stacey Stein, Hyun S. Kim	2019	28
16	Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer European Journal of Cancer ·Richard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii‐Saab, Stacey Stein, Vaibhav Sahai, George P. Keogh, Edward Kim, Ari David Baron, Abby B. Siegel, Afsaneh Barzi, Katherine A. Guthrie, Milind Javle, Howard S. Höchster	2020	26
17	Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma Scientific Reports ·William M. Kamp, Cortlandt M. Sellers, Stacey Stein, Joseph K. Lim, Hyun S. Kim	2019	25
18	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database Journal of the National Comprehensive Cancer Network ·Johannes Uhlig, Michael Cecchini, Amar H. Sheth, Stacey Stein, Jill Lacy, Hyun S. Kim	2021	19
19	A Novel PF/PN Motif Inhibits Nuclear Localization and DNA Binding Activity of the ESX1 Homeoprotein Molecular and Cellular Biology ·Yu‐Ting Yan, Stacey Stein, Jixiang Ding, Michael M. Shen, Cory Abate‐Shen	2000	17
20	DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival. Journal of Clinical Oncology ·Samuel J. Klempner, Johanna C. Bendell, Victoria Villaflor, Laura Tenner, Stacey Stein, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya Chaney, John H. Strickler	2020	15

About Stacey Stein

Stacey Stein is a scholar working on Hepatology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 74 papers that have together received 1.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (20 papers), Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Pancreatic and Hepatic Oncology Research (18 papers), Cancer Treatment and Pharmacology (12 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Cancer Genomics and Diagnostics (11 papers), Gastric Cancer Management and Outcomes (10 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Hepatology (355 citations), Oncology (802 citations), Cancer Research (327 citations), Pulmonary and Respiratory Medicine (387 citations) and Pathology and Forensic Medicine (167 citations). Stacey Stein has collaborated with scholars based in United States, Germany and South Korea. Frequent co-authors include Jill Lacy, Howard S. Höchster, Hyun S. Kim, Xiangyu Cong, Johannes Uhlig, Marcia S. Brose, Catherine Frenette, Stephen J. O’Keefe, Xiaopan Yao and Baek‐Yeol Ryoo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Radiology, Cancer Medicine and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact